[go: up one dir, main page]

NO20042542L - Anvendelse av ascomycin for behandling av blefarit - Google Patents

Anvendelse av ascomycin for behandling av blefarit

Info

Publication number
NO20042542L
NO20042542L NO20042542A NO20042542A NO20042542L NO 20042542 L NO20042542 L NO 20042542L NO 20042542 A NO20042542 A NO 20042542A NO 20042542 A NO20042542 A NO 20042542A NO 20042542 L NO20042542 L NO 20042542L
Authority
NO
Norway
Prior art keywords
ascomycin
blepharitis
treatment
Prior art date
Application number
NO20042542A
Other languages
English (en)
Inventor
Mario Fsadni
Elisabeth Latour
Piotr Szczesny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042542L publication Critical patent/NO20042542L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20042542A 2001-11-19 2004-06-17 Anvendelse av ascomycin for behandling av blefarit NO20042542L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01127546 2001-11-19
PCT/EP2002/012921 WO2003043633A1 (en) 2001-11-19 2002-11-18 Use of an ascomycin for the treatment of blepharitis

Publications (1)

Publication Number Publication Date
NO20042542L true NO20042542L (no) 2004-06-17

Family

ID=8179285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042542A NO20042542L (no) 2001-11-19 2004-06-17 Anvendelse av ascomycin for behandling av blefarit

Country Status (17)

Country Link
US (2) US20050043286A1 (no)
EP (2) EP1450798A1 (no)
JP (1) JP2005511633A (no)
KR (1) KR20040066825A (no)
CN (1) CN1589144A (no)
AU (1) AU2002366222A1 (no)
BR (1) BR0214244A (no)
CA (1) CA2467549A1 (no)
HU (1) HUP0500698A2 (no)
IL (1) IL161849A0 (no)
MX (1) MXPA04004757A (no)
NO (1) NO20042542L (no)
NZ (1) NZ532963A (no)
PL (1) PL368642A1 (no)
RU (1) RU2004118424A (no)
WO (1) WO2003043633A1 (no)
ZA (1) ZA200403575B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
CA3199736A1 (en) 2020-11-23 2022-05-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198708T1 (de) * 1991-04-26 2001-02-15 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
SE9904863D0 (sv) * 1999-12-30 1999-12-30 Medscand Medical Ab New use
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares

Also Published As

Publication number Publication date
BR0214244A (pt) 2004-09-21
IL161849A0 (en) 2005-11-20
US20080076793A1 (en) 2008-03-27
KR20040066825A (ko) 2004-07-27
RU2004118424A (ru) 2005-05-10
CN1589144A (zh) 2005-03-02
CA2467549A1 (en) 2003-05-30
ZA200403575B (en) 2006-07-26
MXPA04004757A (es) 2004-08-02
EP1754482A1 (en) 2007-02-21
JP2005511633A (ja) 2005-04-28
HUP0500698A2 (en) 2006-08-28
NZ532963A (en) 2007-01-26
PL368642A1 (en) 2005-04-04
US20050043286A1 (en) 2005-02-24
WO2003043633A1 (en) 2003-05-30
EP1450798A1 (en) 2004-09-01
AU2002366222A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
LTPA2019511I1 (lt) Rapamicino darinys, skirtas plaučių vėžio gydymui
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
NO20035156L (no) Fremgangsmåter for brønnbehandling
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20042140L (no) Terapeutiske quionolonforbindelser med 5-HT anatagonistiske egenskaper
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
IL174014A0 (en) Methods for the treatment of endometriosis
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
EE200300396A (et) Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
NO20055010D0 (no) Preparater inneholdende laktulose for behandling av potavirusinfeksjoner
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20042640L (no) Fremgangsmate for fremstilling av ekinocandinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application